



VACCELERATE has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101037867.



JANUARY 18 2023, 16.00-17.00 (CET) U.S. CDC Mpox Vaccine Effectiveness

With Dr. Daniel C. Payne, CDC (Centers for Disease Control and Prevention), Atlanta, GA, US

Mpox is a potentially serious disease caused by infection with the mpox virus. It can be spread through close, personal, often skin-to-skin contact. There are two types of vaccines available in the United States that can prevent mpox.

One of them, JYNNEOS™, is a live, replication-deficient MVA vaccine. It is licensed by the U.S. Food and Drug Administration (FDA) and approved as a two-dose series for the prevention of smallpox and mpox for people aged 18 years and older.

The CDC investigated how case numbers are decreasing when high-risk behavior changes and when people with a risk of being infected are vaccinated with one or two doses of the mpox vaccine.

In this webinar, Daniel Payne will present the CDC's different study approaches on mpox vaccine safety and efficacy, report about differences of symptoms and hospitalization among vaccinated and unvaccinated persons and if there have been any safety concerns or adverse events regarding the use of JYNNEOS.

VACCELERATE, the EU funded clinical research network for the coordination & conduct of European vaccine trials is looking forward to hosting this webinar.

The webinar will be recorded and published on <https://vaccelerate.eu/>.

In cooperation with:



UNIKLINIK
KÖLN



Webinar:

U.S. CDC Mpox Vaccine Effectiveness

Presented by

Dr. Daniel C. Payne

Moderated by

VACCELERATE

Presentation approx. 1 hour including Q&As

Registration:

<https://uni-koeln.zoom.us/meeting/register/tJ0qcOqhrDsrHNEGhb2qY1jLpi95Af5DBnB2>